March 13, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne

PPMD is pleased to learn of the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne in patients aged two years and older. According to Catalyst Pharmaceuticals, Inc., following…

Learn More

January 30, 2024

Watch: Navigating Steroid Choices – Understanding the Process, Pathways, and Policies (Webinar Recording)

Last week, PPMD was joined by Kathy Mathews, MD (Neurologist), Christina Trout, RN, MSN (Clinic Coordinator), and Rachel Kinn, PharmD, BCPPS (Pharmacist) from the University of Iowa to discuss decision making regarding steroids. In recent…

Learn More

December 1, 2023

Watch: AGAMREE® Approval with Catalyst Pharmaceuticals, Inc. (Webinar Recording)

PPMD was recently joined by Catalyst Pharmaceuticals to review the recent FDA approval of AGAMREE (vamorolone), a new steroid approved for the treatment of Duchenne.  Amy Grover, Catalyst’s Senior Director of Patient Advocacy, introduced the…

Learn More

November 6, 2023

WATCH: AGAMREE Approval – What this means for you & your family (Webinar recording)

PPMD was recently joined by Dr. Aravindhan Veerapandiyan of Arkansas Children’s Hospital to discuss the FDA’s recent approval of AGAMREE (vamorolone), a new steroid approved for the treatment of Duchenne muscular dystrophy in individuals aged…

Learn More

October 26, 2023

FDA Grants Approval to AGAMREE® (Vamorolone)

PPMD is excited to learn that the FDA has granted approval to AGAMREE® (vamorolone), a dissociative steroid indicated for individuals diagnosed with Duchenne muscular dystrophy from age 2 years and older.  AGAMREE® is a first-in-class…

Learn More